NCT04776135

Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube

A Phase I, Randomized, Open-Label, Crossover-Design, Single-Dose Study to Investigate the Safety, Tolerability and Comparative Bioavailability of Oral Edaravone Administered Orally and Via a Nasogastric Tube (NGT) in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To investigate the comparative bioavailability of edaravone oral suspension administered orally and via a nasogastric tube in healthy adult subjects

Conditions

• Healthy Adult Subjects

Interventions

Type	Name	Description
DRUG	MT-1186	Suspension

Timeline

• Start date: 2021-02-26
• Primary completion: 2021-04-01
• Completion: 2021-04-16
• First posted: 2021-03-01
• Last updated: 2026-01-07
• Results posted: 2024-01-08

Locations

1 site across 1 country: Japan

Regulatory

• FDA-regulated drug study